Common Technical Document (CTD) Dossier Writing

BlueReg consultants can work in close collaboration with your experts to author, review and update your CTD (pharmaceutical, non-clinical and clinical) as required for new marketing authorization application (MAA) submissions or during the lifecycle of the medicinal product. Gap analysis or conversion from Notice to Applicants (NtA) to CTD format on multiple products according to your timelines can be performed.

 

 

Our experts

Associated News

FDA GUIDANCE – COVID-19

BlueReg continues to monitor the changes in the regulatory guidance and we wish to share...

Learn more

How antibody testing can help us fight COVID-19 ?

There is a high demand around the need for antibody testing and the media frenzy...

Learn more

BlueReg continues to expand in the US opening its second North American office in Boston

Cambridge, Massachusetts, USA, December 13 2019, BlueReg, the consulting organization for life sciences companies, is...

Learn more